A new study in the Journal of Infection by Dr. Tristan Clark, et al. titled “Diagnostic accuracy of the FebriDx host response point-of-care test in patients hospitalised with suspected COVID-19” identifies the FebriDx® test as a rapid, highly accurate, and affordable ‘front door triage tool’ to help healthcare providers differentiate viral from bacterial infection in patients with suspected COVID-19. In this study of 251 patients, FebriDx showed high diagnostic accuracy and speed for identifying a viral infection when compared to PCR for confirming COVID-19.
- Click here to access the study.
Lumos Diagnostics Appoints Three Industry Leaders as Independent Directors
Lumos Diagnostics announced today the expansion of its board with the appointment of three new independent directors to support the continued growth of the company’s rapid point-of-care diagnostic products and services business.